| Proportions recommending ‘neostatin’, % (95% CI) | % (95% CI) χ2 statistics |
|
Level 1, NNT = 34, survival gain = 9 months | 39.5 (28.7 to 50.3) | 25.6 (15.8 to 35.4) | 32.7 (25.4 to 40.0) | 13.9 (-0.5 to 28.3) χ2 = 3.5, P = 0.062 |
|
Level 2, NNT = 17, survival gain = 17 months | 49.3 (37.9 to 60.8) | 31.3 (21.0 to 41.5) | 40.0 (32.2 to 47.8) | 18.1 (2.9 to 33.3) χ2 = 5.3, P = 0.022 |
|
Level 3, NNT = 9, survival gain = 32 months | 52.4 (41.5 to 63.3) | 43.2 (32.3 to 54.1) | 47.9(40.1 to 55.6) | 9.2 (-6.0 to 24.5) χ2= 1.4, P= 0.238 |
|
Trend analysisa |
Odds ratio per level (95% CI) | 1.3 (1.0 to 1.8) | 1.5 (1.1 to 2.1) | | |
Odds ratio for interaction term format × level (95% CI) | 1.2 (0.7 to 1.8) | | |
|
| Evaluation of ‘neostatin’ on a 0-10 scale,b score (95% CI) | Mean (95% CI), rank sum statistics |
|
Level 1, NNT = 34, survival gain = 9 months | 5.2 (4.6 to 5.8) | 4.7 (4.1 to 5.3) | 5.0 (4.6 to 5.4) | 0.5 (-0.3 to 1.4) |z| = 1.3, P= 0.189c |
|
Level 2, NNT = 17, survival gain = 17 months | 6.2 (5.7 to 6.8) | 5.0 (4.4 to 5.6) | 5.6 (5.2 to 6.0) | 1.2 (0.4 to 2.0) |z| =3.1, P= 0.002c |
|
Level 3, NNT = 9, survival gain = 32 months | 6.1 (5.6 to 6.6) | 5.5 (4.9 to 6.2) | 5.8 (5.4 to 6.2) | 0.6 (-0.3 to 1.4) |z| = 1.1, P= 0.264c |
|
Trend analysisd |
Regression coefficient per level | 0.42 (0.03 to 0.81) | 0.41 (-0.03 to 0.85) | | |
Regression coefficient for interaction term format x level (95% CI) | -0.01 (-0.59 to 0.58) | | |